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A model for the evolution of mammalian cysteine proteinase inhibitors has been constructed on the basis 
of sequence homology. This model suggests that the diversity of cysteine proteinase inhibitors has evolved 
from two ancestral units forming the building blocks of stefin and cystatin. Gene triplication of the archety- 
pal inhibitor generated the kininogen heavy chain which contains three cystatin-like copies. Hence, the su- 
perfamily of mammalian cysteine proteinase inhibitors is constituted by at least three distinct families, with 
stetin, cystatin and kininogen as their prototypes. 
Cysteine proteinase inhibitor Stejin Cystatin 
1. INTRODUCTION 
Inhibitors of cysteine proteinases are present in 
tissues and body fluids of mammalian species 
[1,2]. By the criterion of their M,, cysteine pro- 
teinase inhibitors (CPIs) form 2 classes [3]: low-M, 
CPIs including stefin and cystatin, and high-M, 
CPIs represented by the kininogens (also termed (Y- 
CPIs). The peptapeptide Gln-Val-Val-Ala-Gly pre- 
sent in most of the known mammalian CPIs is 
believed to form part of the reactive site of the in- 
hibitors [ 1,4]. Two copies of this consensus peptide 
are harbored by human low-M, and high% 
kininogen thus suggesting that their common 
heavy chain [5] might be composed of 2 inhibitor 
domains [4] capable of interacting with cysteine 
proteinases [6,7]. 
To date, the evolutionary relationship among 
the various CPIs has remained largely obscure. 
Here, we demonstrate that the superfamily of 
mammalian CPIs encompasses at least 3 distinct 
Kininogen Evolution Sequence homology 
families, i.e. the stefins, cystatins and kininogens, 
which have evolved from common ancestors. 
2. MATERIALS AND METHODS 
2.1. Computer program RELATE 
This program compares all segments of a length 
of 25 amino acids from one sequence with all 
segments of identical length from another [8]. A 
segment score is accumulated by adding the pair 
scores of the corresponding segments. The 
statistical significance of the relationship is 
evaluated by determining the segment scores for 
100 randomly permuted sequences and expressing 
the comparison scores in standard deviation (SD) 
units. Scores 2 3.0 SD are considered to indicate 
significant sequence homology. 
2.2. Hydropathic index 
The hydropathy profiles were calculated using 
the moving segment approach which continuously 
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Fig. 1. Sequence homologies between stefin-like inhibitors, the human kininogen heavy chain repeats and cystatin-like 
inhibitors. Stefin-like inhibitors: hu ste, stefin from human granulocytes [12]; hu CPI B, cysteine proteinase inhibitor 
B from human liver (also named cystatin B) [23]; ra ep TPI, thiol proteinase inhibitor from rat epidermis [13]; ra li 
TPI, thiol proteinase inhibitor from rat liver [14]. Kininogen repeats: AlBl, A2B2, A3B3, internal repeats of the human 
kininogen heavy chain (Kellermann et al., submitted). Cystatin-like inhibitors: hu cys, cystatin (y-trace) from human 
plasma [3,15]; hu SAP, acidic protein from human saliva [16]; bo CPI, cysteine proteinase inhibitor from bovine 
colostrum [17]; ch cys, cystatin from chicken egg white [18,19]. Allowance for gaps (indicated by dashes) has been made 
to improve the alignment. Residues identical among the internal repeats of the kininogn heavy chain are boxed. 
Sequence identities among the kininogen repeats and at least one of ihe other inhibitors are shaded. The solid bar marks 
the potential reactive sites. Numbers indicate the relative positions of the residues in the amino acid sequences. Asterisks 
locate carbohydrate attachment sites. AC, acetyl; Z, pyroglutamic acid. 
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determines the average hydropathy within a seg- 3.2. Sequence homologies among cysteine 
ment length of 9 amino acids as it advances proteinase inhibitors 
through the sequence [9]. The sequences of mammalian low-~% CPIs and 
3. RESULTS 
3.1. Internal homologies in the human kininogen 
heavy chain 
Search for internal homologies in the heavy 
chain shared by low-M, and high-M, kininogen 
(Kellermann et al., submitted) has led to the iden- 
tification of 3 internal repeats spanning from 
residues 1 to 116, 117 to 238 and 239 to 360 (fig.1). 
Significant sequence homologies (scores from 3.87 
to 12.27) were found among these repeats (table 1). 
Thus, evolvement of the heavy chain of the human 
kininogens by gene triplication can be envisaged 
[lo]. The lengths of the internal repeats vary from 
116 to 122 amino acids. Considering the underly- 
ing pattern of sequence homology, each of these 
long repeats can be subdivided into an N- 
terminally located portion of 85-91 amino acids 
(referred to as segment ‘A’) and a stretch of 31 
amino acids (‘B’) positioned at their C-terminus. 
The entire structure of the human kininogen heavy 
chain is then schematically represented by 
AlBl-A2B2-A3B3 or (AB)s. Similar patterns of 
tandemly repeated AB units are found in the rat 
and bovine kininogens (not shown). Among the 
A/B segments, the pairs A2/A3 and Bl/B2 had 
the highest scores (12.91 and 22.23) indicating that 
they have diverged more recently in evolution. 
of human kininogen repeats Al, A2, A3, Bl, B2, 
and B3 are aligned in fig.1. By the criterion of se- 
quence homology, the low-M, CPIs fall into 2 
categories: the stefin group (fig.1, upper) with a 
moderate sequence homology to the kininogen AB 
repeats, and the cystatin group (fig.1, lower) with 
a considerable homology to the AB repeats. The 
stefin-type inhibitors share a single region of ex- 
tended sequence homology (‘homology box’) with 
the kininogen A segment centered around the pro- 
posed reactive site. Only few additional sequence 
identities are present in the peripheral portions of 
these inhibitors. Unlike the stefin group, the 
cystatin-type inhibitors share 2 homology boxes 
with the kininogen repeats. The first box holds the 
reactive site residues embedded in kininogen seg- 
ment A. The second homology box is located near 
the C-terminus of the inhibitors and covers portion 
B of the kininogen repeats. This latter homology 
box is not found in the stefin-like inhibitors; 
rather, their sequences top 13 amino acids after 
the start of segment B (fig.1, bottom). 
In a quantitative approach, we have evaluated 
the sequence similarities between the kininogen 
repeats and the various low-M, CPIs by the 
RELATE program [8]. Table 1 lists the resulting 
scores. A significant homology to at least one of 
the internal repeats was found for each of the low- 
A4, CPIs except for rat epidermal TPI. Mean scores 
Table 1 
Sequence homologies between the internal repeats AlBl, A2B2, and A3B3 of the human kininogen heavy 
chain, stefin-like inhibitors and cystatin-like inhibitors 
AlBl A2B2 A3B3 hu ste hu CPI B ra ep rali hu cys hu SAP bo CPI ch cys 
TPI TPI 
AlBl - 3.89 3.87 0.39 2 64 1.96 3.14 1.56 0.70 3.15 4.89 
A2B2 3.89 - 12.27 1.38 1.04 0.83 2.52 4.32 1.52 5.14 5.02 
A3B3 3.87 r2.27 - 6.01 3.f9 1.80 4m 6.26 8.37 10.25 5.99 
Segment comparison scores 2 3.0 SD units indicating significant homology among 2 sequences are shaded. 
The acronyms from fig.1 are used 
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of 4.76 and 2.41 were calculated for the cystatin- 
like and stefin-like CPIs. This indicates that the 
cystatin-type inhibitors are more closely related to 
the heavy chain repeats than the stefin-like in- 
hibitors. Along this line, 2 of the 4 cystatin-like in- 
hibitors, but not a single stefin-like inhibitor had 
significant sequence homologies to each of the 3 
AB repeats. From these results we conclude that 
the kininogen heavy chain contains 3 copies of a 
cystatin-like inhibitor rather than of a stefin-like 
inhibitor. 
Among the various AB repeats, A3B3 had the 
most pronounced homology to low-M, CPIs (mean 
score 5.73), while A2B2 and AlBl showed 
significantly lower relatedness (mean scores 2.72 
and 2.30). This suggests that the A3B3 domain 
which precedes the kinin segment in mammalian 
kininogens has been best conserved during the 
evolution of mammalian CPIs (vide infra). Our 
conclusion is corroborated by the fact that the 
hydropathy profile of human cystatin matches 
almost perfectly with that of A3B3, while the cor- 
responding profile of stefin fits only moderately 
(fig.2). 
3.3. Evolution of mammalian cysteine proteinase 
inhibitors 
Comparison of the known sequences of 12 CPIs 
revealed (table 2) that the superfamily of mam- 
f 
hu ste 
+m 
L, 1 1 1 I I 1 
1 25 50 75 100 125 
sequence number 
Fig.2. Hydropathy profiles of human cystatin (hu cys), 
internal repeat A3B3 of the human kininogen heavy 
chain (A3B3), and human stefin (hu ste). Numbers 
indicate relative positions of the residues in the amino 
acid sequences. Gaps are introduced as in fig.1. 
Table 2 
Mean segment comparison scores (SD units) for the 
members of the superfamily of mammalian cysteine 
proteinase inhibitors 
kin CYs ste 
kin 69.12 7.73 2.59 
=ys 7.73 32.57 4.28 
ste 2.59 4.28 24.56 
Highest scores identifying the kininogen family (kin), 
the stefin family (ste) and the cystatin family (cys) are 
shaded. Sequence data sources for the heavy chains of 
human kininogens (Kellermann et al., submitted), 
bovine kininogens [20] and rat kininogens [21,22] are as 
indicated 
malian CPIs is constituted by 3 well-defined 
families, one of which containing the kininogen 
heavy chains (‘kininogen family’), another com- 
prising the stefin-type inhibitors (‘stefin family’), 
and a third holding the cystatin-related inhibitors 
(‘cystatin family’). Typically, sequence homologies 
among the members of each family were high 
(mean scores from 24.56 to 69.12), while those 
among the members of different families were low 
though mostly significant (mean scores from 2.59 
to 7.73). The data from table 2 rank the pairs of 
CPI families according to their mean comparison 
scores in the order kininogens/cystatins (7.73), 
cystatins/stefins (4.28) and stefins/kininogens 
(2.59). 
On the basis of these findings we have con- 
structed a scheme for the evolution of mammalian 
CPIs (fig.3). This model predicts that the diversity 
of mammalian CPIs has evolved from 2 ancestral 
units A and B. The stefin progenitor represents the 
archetype of the whole superfamily in that it com- 
prises a single A unit. The cystatins have acquired 
a second element (B), possibly by gene fusion thus 
forming the prototype of an AB unit. Then, in a 
gene duplication event, intermediate (AB)z 
molecules were formed. Eventually, another gene 
duplication gave rise to the present day (AB)3 form 
of the kininogen heavy chains. At present, the 
mode and time point of the acquirement of the 
224 
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;B31 
Fig.3. Genealogy of mammalian cysteine proteinase 
inhibitors. ‘A’ denotes the N-terminal portion of the 
long internal repeats of human kininogens heavy chain, 
and ‘B’ the corresponding C-terminal segment. Asterisks 
mark the potential reactive sites, 
other constituents of the kininogens, i.e. the kinin 
region and the light chain(s), are still obscure. 
4. DISCUSSION 
The model for the evolution of mammalian cys- 
teine proteinase inhibitors proposed here has 
several intriguing implications. First, it strongly 
suggests that the kininogen heavy chain encom- 
passes 3 copies of an archetypal cystatin and might 
thus represent a triple-headed inhibitor of cysteine 
proteinases. Second, it provides a rationale for the 
nomenclature of mammalian cysteine proteinase 
inhibitors. Third, it predicts that the kininogens 
have descended from a primordial (AB)2 inhibitor 
presently unknown in mammalian or non- 
mammalian species. 
4.1. Kininogens us multi-headed inhibitors 
In view of the 3 cystatin blocks establishing the 
kininogen heavy chain one might expect that the 
kininogens are trivalent inhibitors. However, in- 
spection of the sequence portions holding a poten- 
tial reactive site indicates that only repeats A2B2 
and A3B3 have conserved the consensus equence 
Q-V-V-A-G, while the AlBl domain has almost 
entirely lost this sequence (cf. fig. 1). It is tempting 
to hypothesize that at most 2 of the 3 internal 
repeats expose functionally active inhibitor sites, 
i.e. A2B2 and A3B3. Only recently, this conclusion 
has been confirmed in an elegant study by Salvesen 
et al. [ll]. 
4.2. Nomenclature of mammalian cysteine 
proteinase inhibitors 
In light of the newly established evolutionary 
model for mammalian cysteine proteinase in- 
hibitors, consequences as to the nomenclature of 
these inhibitors have to be drawn. Clearly, by the 
criterion of sequence homology the CPI super- 
family comprises 3 distinct families which we have 
named according to their prominent members: the 
stefin family, the cystatin family and the kininogen 
family. Using this classification system, all CPIs 
for which sequence data are presently available can 
be assigned to one of the 3 families without am- 
biguity or overlapping. Other criteria such as M,, 
disulfide content and prevalent occurrence (intra- 
vs extracellular) might also be considered for the 
classification of CPIs [ 1,2]. Unlike the former, 
these latter criteria per se do not meet the require- 
ment of an unequivocal assignment unless they are 
combined. 
4.3. Double-headed cysteine proteinase inhibitors 
Our model for the evolution of the mammalian 
CPIs predicts binary precursor(s) composed of 2 
cystatin-like AB units. At present, no such in- 
hibitors are known. It seems worthwhile to look 
for these evolutional intermediates, as (AB)z in- 
hibitors would provide the missing link between 
the cystatins and the kininogens. It is also an- 
ticipated that the predicted binary inhibitors 
should give us an idea as to the time point of the 
fusion of the various gene elements coding for the 
kininogen heavy chain, the kinin and the light 
chain portions [lo]. Thus, the finding of such 
primordial inhibitors might provide important 
clues to the deeper understanding of the pedigree 
of the kininogens and hence of the genealogy of 
mammalian cysteine proteinase inhibitors. 
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